| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/24/2003 | WO2003107006A1 Oxaliplatin anti-resistance agent |
| 12/24/2003 | WO2003106974A2 Diagnosis and treatment of chemoresistant tumors |
| 12/24/2003 | WO2003106970A2 P27 prevents cellular migration |
| 12/24/2003 | WO2003106707A1 Method for detecting increased susceptibility to tumours |
| 12/24/2003 | WO2003106669A1 Purified pkb ser 473 kinase and uses thereof |
| 12/24/2003 | WO2003106660A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 12/24/2003 | WO2003106622A2 Methods for treatment of acute lymphocytic leukemia |
| 12/24/2003 | WO2003106496A1 Antibodies, peptides and vaccines against hiv-1 virus |
| 12/24/2003 | WO2003106450A1 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 12/24/2003 | WO2003106445A1 Compounds and methods for controlling bacterial virulence |
| 12/24/2003 | WO2003106426A1 Compounds, compositions, and methods |
| 12/24/2003 | WO2003106385A2 Process for screening fungitoxic compounds |
| 12/24/2003 | WO2003105903A1 Antifungal medicinal composition |
| 12/24/2003 | WO2003105902A1 Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent |
| 12/24/2003 | WO2003105901A2 New medical indication |
| 12/24/2003 | WO2003105900A1 Regulation of secretory phospholipase a2 group iia |
| 12/24/2003 | WO2003105897A1 Combined use of a modulator of cd3 and a glp-1 compound |
| 12/24/2003 | WO2003105896A1 Combined use of a modulator of cd3 and a beta cell resting compound |
| 12/24/2003 | WO2003105881A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 12/24/2003 | WO2003105872A1 Anti-spasmodic comprising xenon |
| 12/24/2003 | WO2003105868A1 Novel maxi-k channel blockers, methods of use and process for making the same |
| 12/24/2003 | WO2003105867A1 Quaternised ammonium cyclodextrin compounds |
| 12/24/2003 | WO2003105862A1 In-vivo energy depleting strategies for killing drug-resistant cancer cells |
| 12/24/2003 | WO2003105855A1 Mitotic kinesin inhibitors |
| 12/24/2003 | WO2003105852A1 Use of dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation |
| 12/24/2003 | WO2003105847A1 Ophthalmic compositions for treating ocular hypertension |
| 12/24/2003 | WO2003105844A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions |
| 12/24/2003 | WO2003105838A2 Metabolite |
| 12/24/2003 | WO2003105833A1 Formulation of nefopam and its use in the treatment of pain |
| 12/24/2003 | WO2003105832A1 Use of nefopam for the treatment of nausea or emesis |
| 12/24/2003 | WO2003105830A1 Medicinal compositions improving brain function and method for improving brain function |
| 12/24/2003 | WO2003105828A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 12/24/2003 | WO2003105818A1 Quinone-based remedies for liver diseases |
| 12/24/2003 | WO2003105815A1 Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression |
| 12/24/2003 | WO2003105806A1 Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof |
| 12/24/2003 | WO2003105781A2 Ophthalmic compositions for treating ocular hypertension |
| 12/24/2003 | WO2003105780A2 A dry powder oligonucleotide formulation, preparation and its uses |
| 12/24/2003 | WO2003105775A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 12/24/2003 | WO2003105752A2 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
| 12/24/2003 | WO2003105724A2 Novel maxi-k channel blockers, methods of use and process for making the same |
| 12/24/2003 | WO2003105578A1 Model animals non-responsive to mycobacteria-origin lipoprotein/lipopeptide |
| 12/24/2003 | WO2003095455A3 Substituted pyrazolopyrimidines |
| 12/24/2003 | WO2003091232A3 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 12/24/2003 | WO2003089593A3 Adjuvant enhanced immunotherapy |
| 12/24/2003 | WO2003089568A3 Method of inhibiting restenosis |
| 12/24/2003 | WO2003089007B1 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu |
| 12/24/2003 | WO2003080813A3 Lactobacillus strains |
| 12/24/2003 | WO2003079020A3 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
| 12/24/2003 | WO2003077892A3 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases |
| 12/24/2003 | WO2003075926A8 Use of proton pump inhibitors for the treatment of airway disorders |
| 12/24/2003 | WO2003075015A3 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 12/24/2003 | WO2003074025A3 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 12/24/2003 | WO2003072026A3 Method of reducing and treating uvb-induced immunosuppression |
| 12/24/2003 | WO2003070182A3 Sodium channel blockers |
| 12/24/2003 | WO2003068224A3 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases |
| 12/24/2003 | WO2003068166A3 Treatment of ophthalmic disorders using urea and urea derivatives |
| 12/24/2003 | WO2003066806A3 Therapeutic use of aziridino compounds |
| 12/24/2003 | WO2003066048A3 Use of 15-lipoxygenase inhibitors for treating and preventing bone loss |
| 12/24/2003 | WO2003064685A3 Genetic polymorphisms in the preprotachykinin gene |
| 12/24/2003 | WO2003063826A3 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same |
| 12/24/2003 | WO2003061703A9 Methods for treatment of multiple sclerosis with statins |
| 12/24/2003 | WO2003057162A3 Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
| 12/24/2003 | WO2003051299A3 Sulfhydryl rifamycins and uses thereof |
| 12/24/2003 | WO2003047611A3 Ptp10d, tec and edtp involved in triglycerid-metabolism |
| 12/24/2003 | WO2003045429A3 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 12/24/2003 | WO2003035046A3 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 12/24/2003 | WO2003032963A3 Method of reducing type 2 diabetes in high risk patients |
| 12/24/2003 | WO2003022207A3 Method and composition for reducing sebum secretion in mammals |
| 12/24/2003 | WO2003020280B1 Compositions and use thereof in the treatment of cancer |
| 12/24/2003 | WO2003000196A3 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 12/24/2003 | WO2002102990A8 Fibroblast growth factor and nucleic acid encoding same |
| 12/24/2003 | WO2002092764A3 Transgenic animal model of bone mass modulation |
| 12/24/2003 | WO2002068548A8 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 12/24/2003 | WO2002058692A3 Halogenated composition, method for preparing same and uses thereof |
| 12/24/2003 | WO2002040006A3 Treatment of anxiety disorders |
| 12/24/2003 | WO2002038730A3 Novel human potassium channel beta subunit |
| 12/24/2003 | WO2002034204A8 Calcilytic compounds |
| 12/24/2003 | WO2002026805A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/24/2003 | WO2001085193A8 Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
| 12/24/2003 | CN1132011C Method for determining ready compound able to regulate cell proliferative diseases |
| 12/24/2003 | CA2491846A1 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
| 12/24/2003 | CA2489791A1 Combinations of pde-v inhibitors and nk1 antagonists for the treatment of anxiety or depression |
| 12/24/2003 | CA2489764A1 Method for detecting increased susceptibility to tumours |
| 12/24/2003 | CA2489726A1 Diagnosis and treatment of chemoresistant tumors |
| 12/24/2003 | CA2489605A1 Oxaliplatin anti-resistance agent |
| 12/24/2003 | CA2489367A1 Compounds, compositions, and methods |
| 12/24/2003 | CA2489315A1 Formulation of nefopam and its use in the treatment of pain |
| 12/24/2003 | CA2489312A1 Modulation of activation of glucocorticoid receptors .beta.-breakdown products of glucocorticoids |
| 12/24/2003 | CA2489306A1 Use of nefopam for the treatment of nausea or emesis |
| 12/24/2003 | CA2488884A1 Novel maxi-k channel blockers, methods of use and process for making the same |
| 12/24/2003 | CA2488845A1 Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension |
| 12/24/2003 | CA2488802A1 Ophthalmic compositions for treating ocular hypertension |
| 12/24/2003 | CA2488752A1 Novel maxi-k channel blockers, methods of use and process for making the same |
| 12/24/2003 | CA2488708A1 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 12/24/2003 | CA2488643A1 Coated particles, methods of making and using |
| 12/24/2003 | CA2488138A1 Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent |
| 12/24/2003 | CA2485751A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions |
| 12/24/2003 | CA2485090A1 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
| 12/23/2003 | US6667404 Retroviral protease inhibiting compounds |
| 12/23/2003 | US6667344 Formoterol, or a derivative; long term storage stability |